Future studies, particularly those incorporating AD-specific biomarkers and accessible blood biomarkers such as glial fibrillary acidic protein to evaluate the severity of neuroinflammation [52], would be invaluable for determining the effects of eradication therapy on incident dementia. The gene discussed is GFAP; the disease is dementia.